Stock Mover of the Day: After Today’s Big Increase, Is Tetraphase Pharmaceuticals Inc’s Near-Term Analysis Positive?

Stock Mover of the Day: After Today's Big Increase, Is Tetraphase Pharmaceuticals Inc's Near Term Analysis Positive?

The stock of Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH) is a huge mover today! About 193,368 shares traded hands. Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH) has declined 25.05% since April 26, 2016 and is downtrending. It has underperformed by 30.31% the S&P500.
The move comes after 9 months positive chart setup for the $172.43 million company. It was reported on Nov, 29 by Barchart.com. We have $4.79 PT which if reached, will make NASDAQ:TTPH worth $12.07 million more.

Analysts await Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH) to report earnings on February, 28. They expect $-0.58 earnings per share, down 16.00% or $0.08 from last year’s $-0.5 per share. After $-0.58 actual earnings per share reported by Tetraphase Pharmaceuticals Inc for the previous quarter, Wall Street now forecasts 0.00% EPS growth.

Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH) Ratings Coverage

Out of 11 analysts covering Tetraphase Pharmaceuticals (NASDAQ:TTPH), 1 rate it a “Buy”, 0 “Sell”, while 10 “Hold”. This means 9% are positive. $57 is the highest target while $8 is the lowest. The $32 average target is 614.29% above today’s ($4.48) stock price. Tetraphase Pharmaceuticals has been the topic of 15 analyst reports since August 6, 2015 according to StockzIntelligence Inc. The rating was downgraded by Stifel Nicolaus to “Hold” on Wednesday, September 9. As per Wednesday, September 9, the company rating was downgraded by JMP Securities. Needham downgraded the stock to “Hold” rating in Wednesday, September 9 report. The rating was downgraded by Wedbush to “Neutral” on Wednesday, September 9. The rating was downgraded by Gabelli to “Neutral” on Friday, May 13. The stock has “Buy” rating given by Brean Capital on Thursday, August 6. The company was downgraded on Wednesday, September 9 by SunTrust. On Thursday, August 6 the stock rating was maintained by Needham with “Buy”. The firm has “Market Perform” rating by BMO Capital Markets given on Tuesday, April 12. The stock of Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH) has “Hold” rating given on Wednesday, September 9 by Brean Capital.

According to Zacks Investment Research, “Tetraphase Pharmaceuticals, Inc. is a life science company engaged in developing and commercializing tetracycline based drugs to treat drug-resistant infectious diseases, inflammation, and cancer. Its principal products include eravacycline, an intravenous and oral antibiotic for the treatment of multi-drug resistant Gram-negative infections. The Company’s product under development includes eravacycline oral formulation, TP-834 and TP-271. Tetraphase Pharmaceuticals, Inc. is based in Watertown, Massachusetts.”

Insitutional Activity: The institutional sentiment increased to 1.12 in Q2 2016. Its up 0.26, from 0.86 in 2016Q1. The ratio increased, as 18 funds sold all Tetraphase Pharmaceuticals Inc shares owned while 26 reduced positions. 14 funds bought stakes while 24 increased positions. They now own 21.31 million shares or 7.27% less from 22.99 million shares in 2016Q1.
Tekla Cap Management Limited Liability Company holds 0.03% of its portfolio in Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH) for 192,322 shares. Proshare Advsrs Limited Liability, a Maryland-based fund reported 31,696 shares. Blackrock Institutional Tru Na accumulated 896,369 shares or 0% of the stock. The New York-based Renaissance Technologies Ltd Llc has invested 0.01% in Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH). Alliancebernstein Lp accumulated 0% or 55,400 shares. California State Teachers Retirement Sys owns 76,320 shares or 0% of their US portfolio. Jpmorgan Chase & last reported 2,078 shares in the company. The Minnesota-based Us Bank & Trust De has invested 0% in Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH). Tiaa Cref Investment Mgmt Ltd Liability Corporation accumulated 230,758 shares or 0% of the stock. Invesco Ltd accumulated 0% or 30,843 shares. Blackrock Investment Mngmt Limited Liability Corp last reported 151,120 shares in the company. United Service Automobile Association holds 0% or 65,791 shares in its portfolio. The Massachusetts-based Acadian Asset Mgmt Lc has invested 0% in Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH). Gabelli Funds Ltd Liability Co accumulated 0% or 120,000 shares. Canada Pension Plan Board has 0.03% invested in the company for 1.98M shares.

More notable recent Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH) news were published by: Marketwatch.com which released: “Tetraphase’s stock tumbles 21% to record low” on April 15, 2013, also Fool.com with their article: “Why Tetraphase Pharmaceuticals Dropped 74% of Its Value in 2015” published on January 11, 2016, Fool.com published: “Why Tetraphase Pharmaceuticals Inc Stock Was Annihilated Today” on September 09, 2015. More interesting news about Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH) were released by: Globenewswire.com and their article: “Tetraphase Pharmaceuticals Reports Second Quarter 2016 Financial Results and …” published on August 04, 2016 as well as Quotes.Wsj.com‘s news article titled: “News Tetraphase Pharmaceuticals Inc.TTPH” with publication date: March 22, 2013.

TTPH Company Profile

Tetraphase Pharmaceuticals, Inc. (Tetraphase), incorporated on July 7, 2006, is a clinical-stage biopharmaceutical company. The Firm uses its chemistry technology to create antibiotics for multidrug-resistant infections. The Firm is developing its lead product candidate, eravacycline, a fully synthetic tetracycline derivative, as a spectrum intravenous (IV) and oral antibiotic for use as a first-line empiric monotherapy for the treatment of multidrug-resistant infections, including multidrug-resistant Gram-negative infections. The Firm also develops TP-6076 for multidrug-resistant Gram- negative infections.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Leave a Comment